BANGKOK, Sept 24, 2009 (AFP) - An experimental AIDS vaccine has for the first time cut the risk of infection in humans in what scientists Thursday called a "breakthrough" in the quarter-century fight against the epidemic.
The vaccine reduced the chance of being infected by a third, researchers announced after the world's largest trial of 16,000 volunteers, carried out by the US Army and Thailand's Ministry of Public Health.
The surprising result comes after years of fruitless attempts by the medical world to find an HIV vaccine, including one trial jab that apparently boosted infection rates.
"It is the first demonstration that a vaccine against HIV can protect against infection," Colonel Jerome Kim of the US military HIV research programme told a news conference in Bangkok via videolink.
"This is a very important scientific advance and gives us hope that a globally effective vaccine may be possible in the future," he said.
Thai Public Health Minister Witthaya Kaewparadai said the "outcome of this study is a scientific breakthrough."
The vaccine was a combination of two older drugs that had not reduced infection on their own and the researchers said they were now studying why the two apparently worked together.
The study combined the canarypox vaccine ALVAC, manufactured by Sanofi-Aventis of France, and AIDSVAX, originally made by VaxGen Inc and now licensed to the non-profit Global Solutions for Infectious Diseases.
Researchers said the latest vaccine showed a 31.2 percent efficacy in reducing the risk of HIV infection.
"The outcome represents a breakthrough in HIV vaccine development because for the first time ever there is evidence that HIV vaccine has preventative efficacy," said the research team in a statement.
The vaccine was tested on volunteers -- all HIV negative men and women aged from 18 to 30 -- at average risk of infection in two Thai provinces near Bangkok starting in October 2003.
Half received the vaccine and the rest were given a placebo. Out of the placebo recipients 74 of 8,198 became infected compared with 51 of 8,197 who got the vaccine.
The World Health Organization and the Joint UN Programme on HIV/AIDS congratulated the researchers for the "encouraging" results.
"The study results, representing a significant scientific advance, are the first demonstration that a vaccine can prevent HIV infection in a general adult population and are of great importance," they said in a statement.
The UN said it may not be possible to get licensing permission for the drug at the moment based on the results, and that further studies were needed to determine if the vaccine has the same effect in other parts of the world.
AIDS first came to public notice in 1981 and has since killed at least 25 million people worldwide, and 33 million others are living with AIDS or the HIV virus.
Swift progress in identifying the virus that caused AIDS unleashed early optimism that a vaccine would quickly emerge. HIV destroys immune cells and exposes the body to opportunistic disease.
But out of the 50 candidates that have been evaluated among humans, only two vaccines have made it through all three phases of trials, and both were flops. About 30 vaccines remain in the pipeline.
Scientists were in 2007 forced to abandon two advanced clinical trials of a vaccine by pharmaceutical company Merck after it appeared to actually heighten the risk of AIDS infection.
Sanofi Pasteur, the vaccines division of Sanofi-Aventis, said the results of the latest test, although "modest", were the first concrete demonstration that a vaccine "could one day become a reality."
The Global HIV Vaccine Enterprise, an alliance of researchers, policymakers, donors and advocates that includes the Bill and Melinda Gates Foundation, said it was a "historic day in the 26-year quest to develop an AIDS vaccine."
The International AIDS Vaccine Initiative (IAVI), an organisation that promotes the search for a vaccine, said the trial results were "very exciting and a significant scientific achievement."
The head of the US agency tasked with controlling the spread of infectious disease said it was an important breakthrough.
"These new findings represent an important step forward in HIV vaccine research," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, which provided major funding and logistical support for the study.
But a top AIDS scientist, France's Jean-Francois Delfraissy, warned that the results were "good news but the effect remains modest".
090924
AF090905
Copyright ©AFP 2009. All Rights Reserved. AFP articles contained on the AEGiS web site may not be reproduced, distributed, transmitted, displayed, published or broadcast without AFP's prior written permission. You may make one copy of each article for your personal, non-commercial use only; more copies would require AFP's prior written permission obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP photos or materials. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP stories, photos or graphics. http://www.afp.com/
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the
Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.